Document is current
Any future updates will be listed below
-
Authors
Bliddal, Mette https://orcid.org/0000-0002-7637-3730
Kildegaard, Helene https://orcid.org/0000-0003-1930-5851
Rasmussen, Lotte https://orcid.org/0000-0001-5962-6647
Ernst, Martin https://orcid.org/0000-0001-9003-3823
Jennum, Poul Jørgen https://orcid.org/0000-0001-6986-5254
Mogensen, Stine Hasling https://orcid.org/0000-0002-5684-681X
Pottegård, Anton https://orcid.org/0000-0001-9314-5679
Wesselhoeft, Rikke https://orcid.org/0000-0001-9700-2739
- License Information
-
More Information
Article History
Received: 16 February 2022
Accepted: 20 June 2022
First Online: 6 July 2022
Declarations
:
: Anton Pottegård reports participation in research projects funded by Alcon, Almirall, Astellas, Astra-Zeneca, Boehringer-Ingelheim, Novo Nordisk, Servier and LEO Pharma, all regulator-mandated phase IV-studies, all with funds paid to the institution where he was employed (no personal fees) and with no relation to the work reported in this paper. All other authors declare no conflict of interests.
: The study was registered on the repository at the University of Southern Denmark (10.080). According to Danish legislation, approval from an ethics committee is not required for registry-based studies.
: Not applicable.
: Not applicable.
